Nilsson, Karin H.
Henning, Petra
El Shahawy, Maha http://orcid.org/0000-0001-7122-1191
Nethander, Maria http://orcid.org/0000-0003-3688-906X
Andersen, Thomas Levin http://orcid.org/0000-0002-6981-7276
Ejersted, Charlotte
Wu, Jianyao
Gustafsson, Karin L. http://orcid.org/0000-0003-2082-4886
Koskela, Antti
Tuukkanen, Juha http://orcid.org/0000-0002-1723-6461
Souza, Pedro P. C. http://orcid.org/0000-0001-7266-6061
Tuckermann, Jan http://orcid.org/0000-0003-3691-275X
Lorentzon, Mattias
Ruud, Linda Engström
Lehtimäki, Terho http://orcid.org/0000-0002-2555-4427
Tobias, Jon H.
Zhou, Sirui http://orcid.org/0000-0003-4963-0815
Lerner, Ulf H.
Richards, J. Brent http://orcid.org/0000-0002-3746-9086
Movérare-Skrtic, Sofia http://orcid.org/0000-0001-7982-7438
Ohlsson, Claes http://orcid.org/0000-0002-9633-2805
Funding for this research was provided by:
Adlerbertska Stiftelserna
Academy of Finland (3322098; 286284; 117787)
Cancer Research UK
IngaBritt och Arne Lundbergs Forskningsstiftelse
Knut och Alice Wallenbergs Stiftelse
Article History
Received: 21 January 2021
Accepted: 19 July 2021
First Online: 13 August 2021
Change Date: 6 September 2021
Change Type: Update
Change Details: In the original version of this Article, the given and family names of author Maha EL Shahawy were incorrectly tagged, leading to incorrect indexing. This error has now been corrected. The PDF and HTML versions displayed the name correctly at the time of publication.
Competing interests
: J.B.R. has served as an advisor to GlaxoSmithKline and Deerfield Capital. He has received investigator-initiated grant funding from Eli Lilly, GlaxoSmithKline and Biogen for projects unrelated to this paper. M.L. has received lecture fees from Amgen, Astellas, Lilly, Meda, Renapharma, UCB Pharma, and consulting fees from Amgen, Radius Health, UCB Pharma, Renapharma, and Consilient Health. The other authors declare no competing interests.